Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 9/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 13/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.47 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | CSF1R | P07333 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | FLT1 | P17948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15722709 | 0.85 | AURKA (0.56) | MEN1KMT2AGSK3BPIK3C3AURKA | |
| SCHEMBL12105469 | 0.82 | AURKA (0.46) | MEN1KMT2AGSK3BAURKAAURKB | |
| SCHEMBL12105473 | 0.82 | AURKA (0.43) | MEN1KMT2AGSK3BAURKAAURKB | |
| SCHEMBL16065335 | 0.82 | KMT2A (0.49) | MEN1KMT2AGAASMN1; SMN2GSK3B | |
| SCHEMBL220647 | 0.81 | PAK4 (0.57) | MEN1KMT2AGSK3BPIK3C3AURKA | |
| SCHEMBL12102875 | 0.81 | AURKA (0.65) | GSK3BAURKAAURKBPAK4DAPK3 | |
| SCHEMBL15704900 | 0.80 | IGF1R (0.52) | MEN1KMT2AGAASMN1; SMN2PIK3C3 | |
| SCHEMBL61333 | 0.79 | KMT2A (0.53) | MEN1KMT2AGAASMN1; SMN2AURKA | |
| SCHEMBL12105461 | 0.79 | AURKA (0.52) | MEN1KMT2AGSK3BPIK3C3AURKA | |
| SCHEMBL12102888 | 0.77 | GSK3B (0.50) | MEN1KMT2AGSK3BPIK3C3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269732-A1 | DRUG DISCOVERY METHODS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2008131103-A2 | DRUG DISCOVERY METHODS FOR AURORA KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269732-A1 | DRUG DISCOVERY METHODS | AURKB, AURKC, AURKA | MEN1 1110/4885KMT2A 687/4885GAA 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.